Skip to main content
Biomind Labs logo

Biomind Labs — Investor Relations & Filings

Ticker · BMND LEI · 254900YBPPG0XSZOE887 NEO Professional, scientific and technical activities
Open in API
Filings indexed 196 across all filing types
Latest filing 2025-11-18 Management Reports
Country CA Canada
Listing NEO BMND

About Biomind Labs

https://www.biomindlabs.com/

Biomind Labs is a biotechnology research and development company focused on creating novel pharmaceutical drugs for patients suffering from neurological and psychiatric disorders. The company employs an R&D acceleration platform to develop next-generation formulations, including those based on key endogenous substances. A core technological focus is the integration of nanotech delivery systems to target the underlying drivers of disease.

Recent filings

Filing Released Lang Actions
Annual MD&A (amended) - English.pdf
Management Reports Classification · 1% confidence The document is an 'Amended & Restated Management's Discussion and Analysis' (MD&A) for Biomind Labs Inc. for the year ended December 31, 2024. It provides a detailed narrative explanation of the company's business operations, financial outlook, and risk factors, which is the primary function of an MD&A report. While it references financial statements, it is a distinct management report rather than the financial statements themselves or a simple announcement. Therefore, it falls under the Management Reports (MDA) category.
2025-11-18 English
Other material contracts - English.pdf
Capital/Financing Update Classification · 1% confidence The document is a legal agreement titled 'Third Amendment to Financing Agreement' between Biomind Labs Inc. and Union Group Ventures Limited. It specifically outlines an extension of a repayment date for an existing financing arrangement. This falls under the category of updates to company financing activities and capital structure changes.
2025-11-17 English
Statement of executive compensation (form 51-102F6) - English.pdf
Capital/Financing Update Classification · 1% confidence The document is a detailed prospectus supplement describing the terms, pricing, and conditions for the issuance of debt securities (medium-term notes) by La Banque de Nouvelle-Écosse as part of a capital-raising program. It is not an annual or interim report, not a regulatory notice of a vote or management change, and not a simple announcement of report publication. Instead, it provides the actual financing terms for a new securities offering, which falls under “Capital/Financing Update” (CAP).
2025-09-05 French
Annual information form - English.pdf
Annual Report Classification · 1% confidence The document is explicitly titled 'ANNUAL INFORMATION FORM' (AIF) for Biomind Labs Inc. for the year ended December 31, 2024. An Annual Information Form is a specific Canadian regulatory disclosure document that provides material information about a company, its business, and its risks. In the context of the provided filing categories, this document serves as a comprehensive annual disclosure document similar to a 10-K in the US market, as it covers business development, risk factors, corporate structure, and governance. Therefore, it is classified as a 10-K. FY 2024
2025-08-07 English
ON form 13-502F1 (class 1 and 3B reporting issuers - participation fee).PDF
Regulatory Filings Classification · 1% confidence The document is a completed Form 13-502F1 submitted to the Ontario Securities Commission detailing the participation fee for a reporting issuer under OSC Rule 13-502 Fees. It is not an annual or quarterly report, earnings release, proxy or dividend notice, or any other investor-oriented announcement, but rather a regulatory form. It therefore falls under the general “Regulatory Filings” category.
2025-08-07 English
AB form 13-501F1 (class 1 and 3B reporting issuers - participation fee).PDF
Regulatory Filings Classification · 1% confidence The document is a completed Canadian securities commission Form 13-501F1 – a management certification of participation fees for a Class 1 reporting issuer, Biomind Labs Inc. It is a regulatory filing to the Alberta Securities Commission and provides fee calculations, but it is not a financial report (annual/interim), earnings release, dividend notice, director dealing, M&A, or other specific corporate action. It therefore falls under the fallback category of a miscellaneous regulatory filing (RNS).
2025-08-07 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.